Press Releases Events & Presentations Event Details European Association for the Study of the Liver (EASL) Congress 2026 May 27 - May 30, 2026 Supporting Materials Safety, Pharmacokinetics, and Pharmacodynamic Activity of ABI-6250, a First-in-Class Oral Hepatitis D Virus Entry Inhibitor in Healthy Subjects: Interim Results From a Randomized, Blinded, Phase 1a Study 375.2 KB Shareholder Tools Print Email Alerts RSS News Feeds Search Investors
European Association for the Study of the Liver (EASL) Congress 2026 May 27 - May 30, 2026 Supporting Materials Safety, Pharmacokinetics, and Pharmacodynamic Activity of ABI-6250, a First-in-Class Oral Hepatitis D Virus Entry Inhibitor in Healthy Subjects: Interim Results From a Randomized, Blinded, Phase 1a Study 375.2 KB
Safety, Pharmacokinetics, and Pharmacodynamic Activity of ABI-6250, a First-in-Class Oral Hepatitis D Virus Entry Inhibitor in Healthy Subjects: Interim Results From a Randomized, Blinded, Phase 1a Study 375.2 KB
